Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance

Journal of Thoracic Oncology

Volumn 3, Issue 2, 2008, Pages 107-110

  Krysan, Kostyantyn ^a   Lee, Jay M ^a   Dohadwala, Mariam ^a   Gardner, Brian K ^a   Reckamp, Karen L ^b   Garon, Edward ^a   John, Maie St ^a   Sharma, Sherven ^a   Dubinett, Steven M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cyclooxygenase 2; Drug resistance; EGFR TK inhibitor; Epithelial to mesenchymal transition; G protein coupled receptors; Inflammation; NSCLC; PGE2

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; ROFECOXIB;

CANCER RESISTANCE; CELL TRANSFORMATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; EPITHELIUM CELL; HUMAN; INFLAMMATION; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALIGNANT TRANSFORMATION; MESENCHYME CELL; METASTASIS; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 40049084003     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181630ece     Document Type: Article

References (44)

1. T Kosaka Y Yatabe H Endoh Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib Clin Cancer Res 12 2006 5764 5769
2. JA Engelman K Zejnullahu T Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
3. CL Sawyers Cancer: mixing cocktails Nature 449 2007 993 996
4. S Sun JH Schiller M Spinola JD Minna New molecularly targeted therapies for lung cancer J Clin Invest 117 2007 2740 2750
5. JL Arbiser Why targeted therapy hasn't worked in advanced cancer J Clin Invest 117 2007 2762 2765
6. LM Coussens Z Werb Inflammation and cancer Nature 420 2002 860 867
7. MA Huber N Kraut H Beug Molecular requirements for epithelial-mesenchymal transition during tumor progression Curr Opin Cell Biol 17 2005 548 558
8. RL Yauch T Januario DA Eberhard Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients Clin Cancer Res 11 2005 8686 8698
9. S Thomson E Buck F Petti Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition Cancer Res 65 2005 9455 9462
10. SE Witta RM Gemmill FR Hirsch Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines Cancer Res 66 2006 944 950
11. RA Soslow AJ Dannenberg D Rush COX-2 is expressed in human pulmonary, colonic, and mammary tumors Cancer 89 2000 2637 2645
12. K Riedl K Krysan M Pold Multifaceted roles of cyclooxygenase-2 in lung cancer Drug Resist Updat 7 2004 169 184
13. K Krysan H Dalwadi S Sharma Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer Cancer Res 64 2004 6359 6362
14. M Pold LX Zhu S Sharma Cyclooxygenase-2-dependent expression of angiogenic cxc chemokines ena-78/cxc ligand (cxcl) 5 and interleukin-8/cxcl8 in human non-small cell lung cancer Cancer Res 64 2004 1853 1860
15. KM Leahy AT Koki JL Masferrer Role of cyclooxygenases in angiogenesis Curr Med Chem 7 2000 1163 1170
16. M Dohadwala J Luo L Zhu Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44 J Biol Chem 276 2001 20809 20812
17. M Dohadwala RK Batra J Luo Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion J Biol Chem 277 2002 50828 50833
18. MM McKay DK Morrison Integrating signals from RTKs to ERK/MAPK Oncogene 26 2007 3113 3121
19. K Krysan K Reckamp S Sharma PGE2 activates MAPK/Erk pathway in non-small cell lung cancer cells in an EGF receptor-independent manner Cancer Res 65 2005 6275 6281
20. B Charuworn M Dohadwala K Krysan Inflammation-mediated promotion of EMT in NSCLC: IL-1b mediates a MEK/Erk- and JNK/SAPK-dependent downregulation of E-cadherin Proc Am Thorac Soc 2006 D96
21. M Dohadwala SC Yang J Luo Cyclooxygenase-2-dependent regulation of E-cadherin: Prostaglandin E2 induces transcriptional repressors ZEB1 and Snail in non-small cell lung cancer Cancer Res 66 2006 5338 5345
22. JP Thiery Epithelial-mesenchymal transitions in tumour progression Nat Rev Cancer 2 2002 442 454
23. RN Dubois SB Abramson L Crofford Cyclooxygenase in biology and disease FASEB J 12 1998 1063 1073
24. SR Neves PT Ram R Iyengar G protein pathways Science 296 2002 1636 1639
25. ZG Goldsmith DN Dhanasekaran G protein regulation of MAPK networks Oncogene 26 2007 3122 3142
26. E Rozengurt Neuropeptides as growth factors for normal and cancerous cells Trends Endocrinol Metab 13 2002 128 134
27. R Pai B Soreghan IL Szabo Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy Nat Med 8 2002 289 293
28. N Prenzel E Zwick H Daub EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of prohb-EGF Nature 402 1999 884 888
29. FG Buchanan D Wang F Bargiacchi RN DuBois Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor J Biol Chem 278 2003 35451 35457
30. AJ Dannenberg SM Lippman JR Mann Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention J Clin Oncol 23 2005 254 266
31. SM Gadgeel JC Ruckdeschel EI Heath Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC) J Thorac Oncol 2 2007 299 305
32. KJ O'Byrne S Danson D Dunlop Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer J Clin Oncol 25 2007 3266 3273
33. KL Reckamp K Krysan JD Morrow A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer Clin Cancer Res 12 2006 3381 3388
34. C Boccaccio G Sabatino E Medico The MET oncogene drives a genetic programme linking cancer to haemostasis Nature 434 2005 396 400
35. S Gately The contributions of cyclooxygenase-2 to tumor angiogenesis Cancer Metastasis Rev 19 2000 19 27
36. H Dalwadi K Kysan N Heuze-Vourc'h Cyclooxygeanse 2 dependent regulation of STAT3 pathways in NSCLC Clin Cancer Res 11 2005 7674 7682
37. JM Siegfried CT Gubish ME Rothstein Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non-small cell lung cancer Mol Pharmacol 72 2007 769 779
38. OM Fischer S Giordano PM Comoglio A Ullrich Reactive oxygen species mediate met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells J Biol Chem 279 2004 28970 28978
39. D Thuringer L Maulon C Frelin Rapid transactivation of the vascular endothelial growth factor receptor kdr/flk-1 by the bradykinin b2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells J Biol Chem 277 2002 2028 2032
40. GN Rao P Delafontaine MS Runge Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1, and phospholipase C-gamma 1 in rat aortic smooth muscle cells J Biol Chem 270 1995 27871 27875
41. DA Linseman CW Benjamin DA Jones Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells J Biol Chem 270 1995 12563 12568
42. MJ Edelman D Watson X Wang COX-2 expression is a positive predictive factor for celecoxib + chemotherapy in advanced non-small cell lung cancer (NSCLC): CALGB 30203 J Thorac Oncol 1 2006 889 890
43. Reckamp KL, Gardner BK, Figlin RA, et al. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase (MMP)-9 and a decline in serum soluble E-cadherin (sec). J Thorac Oncol . In press.
44. I Csiki DH Johnson Did targeted therapy fail cyclooxygenase too? J Clin Oncol 24 2006 4798 4800